UCLA/UCSF researchers predict future of drug-resistant HIV epidemic

August 30, 2001

The number of drug-resistant HIV cases has already reached epidemic proportions in San Francisco, but transmission of drug-resistant strains is not to blame, reports a new UCLA/UCSF study in the September issue of Nature Medicine.

"The good news is that transmission of drug-resistant HIV will not become a major public health problem," said Dr. Sally Blower, lead author and UCLA professor of biomathematics and AIDS Institute member. "The bad news is that the prevalence of drug-resistant HIV is already high and will continue to substantially increase."

Antiretroviral drugs currently offer the best means for controlling the progression and symptoms of HIV disease. But combination drug therapy, or the triple-drug "cocktail," demands a complicated dosage regimen that is difficult to maintain and often provokes severe side effects.

According to the authors, physicians treating people with HIV may unwittingly contribute to the drug-resistant epidemic if they don't recognize the risks associated with incorrect use of the antiretroviral medications.

"These drugs are as dangerous as chemotherapy," warned Dr. James Kahn, UCSF associate professor of medicine and last author of the study. "General practitioners should not be using them. You really need a skilled HIV specialist to prescribe the medications and closely monitor the patient's adherence and response to treatment."

Blower's team used a mathematical model to understand the evolution of drug-resistant HIV strains in the San Francisco gay community from 1996 to 2001, and to predict the epidemic's growth from 2001 to 2005.

Their theoretical model included such variables as the number of infected drug-sensitive cases, the treatment rate, increases in risky sexual behavior and the rate at which drug-resistant strains of HIV emerge during treatment. Blower's team modeled the evolution of 1,000 different strains of drug-resistant HIV.

Blower's team estimated that only 3 percent of cases in San Francisco were drug-resistant in 1997. However, by 2005, they predict that 42 percent of all HIV cases will be drug-resistant.

Using their mathematical model, the research team determined that the rise in the number of drug-resistant cases was mainly due to the conversion of drug-sensitive cases to drug-resistant cases during antiretroviral therapy. Sexual transmission of drug-resistant virus did not -- and will not -- play a major role in fueling the epidemic of drug resistance. Blower's team estimated that in 2000, only 8 percent of the new HIV drug-resistant infections were due to transmission of resistant strains.

"In the future, the vast majority of new HIV infections will still be drug-sensitive," Blower said. "We predict that even in 2005, only 16 percent of new infections will be drug-resistant." The team also determined that the transmission of drug-resistant strains has not increased, and will not increase, the overall number of new HIV infections.

Blower and her co-authors point out that physicians and policymakers can take steps to minimize the prevalence and the transmission of drug-resistant HIV. Based upon their findings, they recommend four epidemic-control strategies:

1. Delay drug treatment as long as possible in order to maximize the medical benefit and reduce side effects.

2. Create clinical centers of excellence for HIV/AIDS treatment to most effectively limit the rate of acquired drug resistance.

3. Develop therapies more effective for treating patients with drug-resistant viral strains.

4. Reduce the amount of time a drug-resistant patient is on ineffective therapy.

Despite the predicted high prevalence of drug resistance, the authors emphasize that people shouldn't consider their findings an argument against antiretroviral drug treatment in San Francisco or in developing countries.

"We have shown that the surging number of drug-sensitive HIV cases -- which are due to increases in high-risk sex -- pose a substantially greater public health problem than the transmission of drug-resistant virus," Blower said.

Based on their findings in San Francisco, the researchers strongly advocate the expanded use of antiretroviral drugs in developing countries. However, they caution that these therapies must be administered carefully and coupled with effective efforts to reduce the risk of infection.

"Antiretroviral treatment will do the most good when the patient is ready to follow it. But the optimal timing is a real unknown," Kahn said. "We need scientifically proven guidelines to help HIV specialists work with their patients in making this complicated decision."

The UCLA/UCSF study is discussed in an accompanying News & Views in the same issue of Nature Medicine entitled, "Will the drugs still work? Transmission of resistant HIV," by Andrew Philips of the Royal Free and University College Medical School, London.
-end-
The National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health, and the University of California AIDS Research Program funded the study. Nick Aschenbach and Hayley Gershengorn, research assistants in Blower's lab, are co-authors of the study.

University of California - Los Angeles

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.